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 Abstract 
 Kallikrein-related peptidases (KLKs) are a family of serine 
proteases that were shown to be useful cancer biomarkers. 
KLKs have been shown to be dysregulated in prostate cancer 
(PCa). microRNAs (miRNAs) are short RNA nucleotides that 
negatively regulate gene expression and have been report-
edly dysregulated in PCa. We compiled a comprehensive list 
of 55 miRNAs that are differentially expressed in PCa from 
previous microarray analysis and published literature. Target 
prediction analyses showed that 29 of these miRNAs are pre-
dicted to target 10 KLKs. Eight of these miRNAs were pre-
dicted to target more than one KLK. Quantitative real-time 
(qRT)-PCR demonstrated that there was an inverse correla-
tion pattern in the expression (normal vs. cancer) between 
dysregulated miRNAs and their target KLKs. In addition, 
we experientially validated the miRNA-KLK interaction by 
transfecting miR-331-3p and miR-143 into a PCa cell line. 
Decreased expression of targets KLK4 and KLK10, respec-
tively, and decreased cellular growth were observed. In addi-
tion to KLKs, dysregulated miRNAs were predicted to target 
other genes involved in the pathogenesis of PCa. These data 
show that miRNAs can contribute to KLK regulation in PCa. 
The miRNA-KLK axis of interaction projects a new ele-
ment in the pathogenesis of PCa that may have therapeutic 
implications. 
 Keywords:  cancer pathogenesis;  kallikrein;  KLK;  miRNA; 
 personalized medicine;  prostate;  prostate cancer;  tumor 
markers. 
 Introduction 
 Prostate cancer (PCa) is the most common malignancy in 
the western world. In 2011, it is predicted that there will be 
over 240 000 newly diagnosed cases of PCa in the United 
States (American Cancer Society , 2011 ). The risk of devel-
oping PCa increases with age and is highest after the age 
of 60. The incidence rate of PCa has been on the rise over 
the past three decades, likely due to the recent advances in 
early detection of the disease. The mechanisms underlying 
prostate carcinogenesis is yet to be fully elucidated (Gu and 
Brothman , 2011 ). 
 Kallikrein-related peptidases (KLKs) are family of serine 
proteases well documented in the literature to be dysregu-
lated in a number of cancers including ovarian, prostate, 
brain, and kidney cancers (Yousef et al. , 2001, 2003 ). Many 
members of the KLK family have been reported to be dys-
regulated in PCa and thus are being investigated as possible 
biomarkers for the disease (Emami and Diamandis , 2008 ; 
Seiz et al. , 2010 ). 
 Currently, prostate-specifi c antigen (PSA), which is 
encoded by the human KLK3 gene is the most widely 
adopted biomarker for early detection of PCa. However, 
accumulating evidence suggests the lack of sensitivity and 
specifi city of PSA as a PCa tumor marker. Recent studies 
have shown that human KLK2 is upregulated during PCa 
progression and therefore may have use as a biomarker. 
Diagnostic tests that combine serum KLK2 with total PSA 
(Recker et al. , 2000 ) and free PSA (Stephan et al. , 2006 ) 
have improved the sensitivity and specifi city of detection. 
In addition, KLK4 mRNA was shown to be upregulated 
in PCa tissues (Yousef et al. , 1999 ; Obiezu et al. , 2002 ; Xi 
et al. , 2004 ; Avgeris et al. , 2011 ) and may play a role in 
epithelial to mesenchymal transition (Veveris -Lowe et al., 
2005 ). On the other hand, studies showed that KLK10, a 
potential tumor suppressor, was downregulated in more 
aggressive PCa s (Luo and Diamandis , 2000 ). In a PCa 
cell line, KLK10 mRNA and protein downregulation were 
suggested to be a result of CpG island hypermethylation 
(Sidiropoulos et al. , 2005 ). 
 microRNAs (miRNAs) are small nonprotein-coding RNA 
nucleotides that have been widely described as having impor-
tant biological and regulatory roles in cancer (Garofalo and 
Croce , 2011 ). miRNAs negatively regulate the expression of 
their target genes through complementary, sequence-specifi c 
binding, which leads to negative regulation of the target 
gene by either mRNA degradation or suppression of protein 
translation. miRNAs have been shown to be dysregulated in 
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a wide array of tumors including breast, lung, prostate, ovar-
ian, and kidney cancers (Fendler et al. , 2011 ; White et al. , 
2011 ), and their role in the pathogenesis of these cancers is 
being investigated (Schaefer et al. , 2010b ; White and Yousef , 
2010 ). 
 The interaction between miRNAs and KLKs is emerg-
ing in the literature as a potential new dimension of regu-
lation of carcinogenesis in many tumors including ovarian 
and kidney cancers (Chow et al. , 2008 ; Yousef , 2008 ; White 
et al. , 2010a,b ). Recognizing this relationship will enhance 
our understanding of the mechanisms that control KLK dys-
regulation in PCa and will also shed the light on the down-
stream effector pathways through which miRNAs can affect 
tumor formation and progression. 
 In this study, we aimed to examine miRNA dysregulation 
in PCa and how these dysregulated miRNAs may contri-
bute to KLK dysregulation. We performed target prediction 
analysis to determine potential KLK targets. We also corre-
lated differential expression of miRNAs dysregulated in PCa 
with their target KLK expression using quantitative real-time 
(qRT)-PCR in PCa tissues. We experimentally verifi ed the 
miRNA-KLK interaction in a PCa cell line model and exam-
ined the effect of this interaction on cellular growth. We also 
performed bioinformatics analyses to help understand the 
mechanism of miRNA dysregulation in PCa and how they 
affect KLKs. 
 Results 
 miRNAs dysregulated in PCa can target KLKs 
 A compiled total of 55 miRNAs were reported to be dysregu-
lated in PCa by microarray analysis (Schaefer et al. , 2010a ) 
and multiple literature sources (Table  1 ). Twenty-three miR-
NAs were reported to be upregulated, while 25 were reported 
to be downregulated. There were confl icting reports for the 
dysregulation of seven miRNAs (i.e., reported to be upregu-
lated and downregulated in different studies). We performed 
target prediction analysis on each of the 55 miRNAs and found 
that 29 (53 % ) of them are predicted to target KLKs (Table 1). 
Interestingly, eight of these miRNAs were predicted to target 
more than one KLK gene; e.g., miR-143 is predicted to target 
KLK2, KLK5, KLK10, and KLK13. Also, the same KLK can 
be targeted by more than one miRNA; e.g., KLK10 is predicted 
to be targeted by eight miRNAs including miR-1, miR-143, 
and miR-17-5p. The complexity of these potential interactions 
is shown in Figure  1 . Three miRNAs, miR-24, miR-21, and 
miR-16 were predicted to target both KLK10 and KLK2. 
 KLKs and miRNAs show inverse correlation pattern 
of expression in PCa tissues 
 In order to validate the miRNA-KLK target interaction 
 in vivo , we validated the expressions of miR-21, miR-24, 
 Table 1  A complied list of 55 miRNAs that are dysregulated in PCa. Twenty-nine miRNAs are predicted to target KLKs. 
miRNA Expression in PCa KLK predicted target miRNA Expression in PCa KLK predicted target
let-7a Down - miR-21  up KLK2, KLK10
let-7i Down - miR-221 Up / Down -
miR-1 Up / Down KLK10, KLK13 miR-222 Up / Down -
miR-101 Down - miR-24 Up KLK2, KLK3, KLK7, KLK10
miR-103 Up KLK5 miR-30d Down -
miR-106b Up / down - miR-31 Up KLK10
miR-107 Up / down KLK5 miR-32 Up -
miR-125b Up - miR-320 Up -
miR-126 Down - miR-324-3p Down KLK2
miR-1296 Down - miR-330-3p Down KLK4
miR-133a Up - miR-331-3p Down KLK2, KLK4
miR-133b Down - miR-34a Down KLK13
miR-140 Down KLK6, KLK9 miR-34c Down KLK13
miR-141 Up - miR-363 Down -
miR-143 Down KLK2, KLK5, KLK10, KLK13 miR-370 Down KLK2
miR-145 Down KLK7 miR-449 Down -
miR-146a Down - miR-449a Down KLK13
miR-148a Up / Down - miR-485-3p Up -
miR-15 Down KLK2 miR-486-5p Up KLK11
miR-16 Up / Down KLK2, KLK10 miR-521 Up -
miR-17-5p Down KLK5, KLK7, KLK10 miR-7 Down KLK3
miR-193b Up KLK10 miR-766 Up KLK3
miR-194 Up - miR-768-3p Up KLK11
miR-197 Up - miR-801 Down -
miR-200a Up KLK13 miR-92 Up -
miR-200b Up KLK7 miR-96 Up -
miR-205 Down KLK2 miR-99 Down -
miR-20a Up -
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 Figure 1  Dysregulated miRNAs in PCa are predicted to target more kallikreins. 
 The complex interaction between miRNAs and KLKs is shown in the interaction map. Only miRNAs that are predicted to target more than 
one KLK are shown. Two interesting phenomena are observed; one miRNA can target multiple KLKs, and the same KLK can be targeted by 
multiple miRNAs. 
miR-143, and miR-331-3p and their targeting KLKs in PCa 
tissues and matched normal tissue from the same patients. We 
chose these miRNAs because (1) they were signifi cantly dys-
regulated in PCa when compared to normal prostate tissue 
from the same patient; (2) target prediction analysis showed 
that these miRNAs could target KLKs that have been previ-
ously shown to be dysregulated in PCa; and (3) these miRNAs 
have been previously shown to be dysregulated in cancer. 
 When we measured the expression of miR-143 and its 
target KLK2 in 12 pairs of PCa and normal matched pros-
tate tissue from the same patient, we found that 67 % (8/12) 
patients showed increased expression of KLK2. Interestingly, 
when we examined the relationship between the expression 
of KLK2 and its targeting miRNA, miR-143, we identifi ed 
an inverse correlation pattern of expression (Figure  2 A and 
Supplementary Table  1 ), i.e., when there was decreased levels 
of miR-143 in cancer compared to normal, there was increased 
levels of KLK2 expression and vice versa. We also identifi ed 
other miRNAs that are downregulated in PCa and are pre-
dicted to target KLK2. They include miR-15, miR-205, miR-
324-3p, miR-370, and miR-331-3p. miR-143 (Clape et al. , 
2009 ; Peng et al. , 2011 ) and miR-15 (Musumeci et al. , 2011 ) 
have been shown by others to be downregulated in PCa. 
 KLK4 was upregulated in 58 % (7/12) PCa cases studied (data 
not shown) and is predicted to be targeted by two miRNAs, miR-
330-3p and miR-331-3p, that were downregulated in PCa by us 
and others (Epis et al. , 2009 ; Lee et al. , 2009a ). We correlated the 
expression of miR-331-3p and its target KLK4 and found that 
there was an inverse correlation pattern of expression (Figure 
2B and Supplementary Table 1), suggesting that dysregulated 
miRNAs can contribute to KLK dysregulation in PCa. 
 PSA, which was upregulated in 67 % (8/12) PCa tissues 
(data not shown) examined, is predicted to be a putative target 
of miR-7, which was downregulated in PCa. Another study 
showed that miR-7 was downregulated in PCa and can tar-
get epidermal growth factor receptor (ERBB) (Giles et al. , 
2011 ). KLK3 was also predicted to be targeted by miR-24 
and showed an inverse correlation pattern of expression 
(Supplementary Table 1). 
 KLK10, which was shown to be downregulated in 75 % 
(9/12) PCa tissues (data not shown) when compared to nor-
mal matched prostate tissue, is predicted to be targeted by fi ve 
miRNAs that are reported to be upregulated in PCa. These 
include miR-16, miR-193b, miR-21, miR-24, and miR-31. A 
number of studies have shown that miR-21 is upregulated and 
can effect cellular invasion and apoptosis in PCa cell lines 
(Li et al. , 2009b ; Ribas and Lupold , 2010 ). We found that the 
expression of miR-21 and its target KLK10 were inversely 
correlated (Supplementary Table 1). 
 miRNAs can target KLKs and affect cellular growth 
in a PCa cell line 
 In order to experimentally validate the miRNA-KLK interac-
tion, we chose the DU-145 PCa cell line. This cell line model 
proved to be suitable as it has moderate expression of KLK4 
and KLK10 and no expression of miR-331-3p or miR-143, 
respectively. This is ideal for validation experiments as we 
would expect to see decreased KLK expression after transfec-
tion with its targeting miRNA. 
 We fi rst transfected DU-145 cells with miR-331-3p and 
compared the expression of its target, KLK4, before and 
after transfection (Figure  3 A). We found that after trans-
fection with miR-331-3p, there was decreased expression 
of KLK4 when compared to untransfected cells and con-
trol cells ( p < 0.001). We also experimentally validated the 
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 Figure 2  The inverse correlation relationship between miRNAs 
dysregulated in PCa and their target KLKs. 
 Expression changes (cancer/normal) were measured for both 
miRNAs and their target KLKs in pairs of cancer/normal tissues 
form the same patient. (A) Expression changes of miR-143 (cancer/
normal) are inversely correlated to KLK2 expression in PCa tissues. 
(B) The expression changes of miR-331-3p are inversely correlated 
to KLK4 expression. 
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 Figure 3  The effect of dysregulated miRNAs on kallikreins and 
cell proliferation in a PCa cell line model. 
 (A) KLK4 expression was signifi cantly decreased in the DU-145 
cell line after transfection with miR-331-3p when compared to 
untransfected controls and control cells. (B) After transfection with 
either miR-143 or miR-331-3p, cellular growth was decreased in the 
DU-145 cell line model when compared to untransfected controls 
after days 3 and 4 (* p < 0.001, ** p < 0.05). 
miR-143 and KLK10 interaction and found that after trans-
fection with miR-143, KLK10 expression was decreased 
( p < 0.005; data not shown). 
 In order to examine the biological effects of the miRNA-
KLK interaction in PCa, we transfected DU-145 cells with 
either miR-143 or miR-331-3p and measured their effect on 
tumor cell growth. We found that cells transfected with either 
miR-143 ( p < 0.001) or miR-331-3p ( p < 0.05) showed a decrease 
in cellular growth when compared to untransfected cells after 
days 3 and 4 (Figure 3B), suggesting that the miRNA-KLK 
interaction can play a role in PCa pathogenesis. 
 Bioinformatics analysis 
 Identifi cation of miRNA clusters located near the 
KLK cytogenetic locus  Previous reports showed that 
approximately 50 % of human miRNAs are organized into 
clusters within large polycistronic messages (Zhang et al. , 2009 ). 
Using an inter-miRNA cutoff of a distance of 10 000 nucleotides, 
we identifi ed four miRNA clusters that are located around the 
KLK locus (Table  2 ). The fi rst cluster has two miRNAs, the 
second contains three, while the third cluster has 46 miRNAs 
(which is the largest human miRNA cluster), and the fourth 
has three miRNAs. Target prediction analysis determined that 
72 % (39/54) of miRNAs in the clusters were predicted to target 
KLKs. In order to confi rm positive miRNA-KLK interactions, 
these targets need to be experimentally verifi ed. 
 Correlation of miRNA with cytogenetic changes 
in PCa  In order to explore the mechanism of miRNA 
dysregulation in PCa, we compiled a list of frequent 
chromosomal aberrations in PCa and correlated them with 
miRNA dysregulation in the malignancy. We found that there 
were 22 miRNAs that were reported to be dysregulated in PCa 
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 Table 2  Many of the miRNAs that are located in the four clusters around the kallikrein locus are predicted to target KLK. 
Cluster miRNA Cytoband Inter-miRNA distance (nt) Predicted KLK targets a 
1 hsa-miR-330 19q13.31 - KLK2, KLK3, KLK4, KLK5, KLK9, KLK10
hsa-miR-642 19q13.31 35 841 KLK2, KLK3, KLK10
Kallikrein locus
2 hsa-miR-99b 19q13.32 -
hsa-let-7e 19q13.32   105 KLK2, KLK3, KLK6, KLK10, KLK15
hsa-miR-125a 19q13.32   390 KLK2, KLK5, KLK6, KLK10, KLK5
3 hsa-miR-512-1 19q13.33 - KLK2, KLK3, KLK7, KLK10
hsa-miR-512-2 19q13.33   2395 KLK2, KLK3, KLK7, KLK10
hsa-miR-1323 19q13.33   2714
hsa-miR-498 19q13.33   2157 KLK11
hsa-miR-520e 19q13.33   1391 KLK2, KLK10
hsa-miR-515-1 19q13.33   3206 KLK2, KLK3, KLK7, KLK10, KLK13
hsa-miR-519e 19q13.33   855 KLK2, KLK3, KLK5, KLK10, KLK13
hsa-miR-520f 19q13.33   2136 KLK3
hsa-miR-515-2 19q13.33   2764 KLK2, KLK3, KLK7, KLK10, KLK13
hsa-miR-519c 19q13.33   1378 KLK7
hsa-miR-1283-1 19q13.33   1926
hsa-miR-520a 19q13.33   2314 KLK2, KLK3, KLK7, KLK10
hsa-miR-526b 19q13.33   3428 KLK7, KLK10, KLK15
hsa-miR-519b 19q13.33   738 KLK7
hsa-miR-525 19q13.33   2240 KLK2, KLK6, KLK9
hsa-miR-523 19q13.33   768
hsa-miR-518f 19q13.33   1544
hsa-miR-520b 19q13.33   1126 KLK10
hsa-miR-518b 19q13.33   1450
hsa-miR-526a-1 19q13.33   3433 KLK9
hsa-miR-520c 19q13.33   1117 KLK9, KLK10
hsa-miR-518c 19q13.33   1196
hsa-miR-524 19q13.33   2167
hsa-miR-517a 19q13.33   1180 KLK2
hsa-miR-519d 19q13.33   993 KLK5, KLK7, KLK10
hsa-miR-521-2 19q13.33   3160
hsa-miR-520d 19q13.33   3416 KLK2, KLK10
hsa-miR-517b 19q13.33   894
hsa-miR-520g 19q13.33   1024 KLK10
hsa-miR-516b-2 19q13.33   3187 KLK2, KLK3, KLK10
hsa-miR-526a-2 19q13.33   1396 KLK9
hsa-miR-518e 19q13.33   2852
hsa-miR-518a-1 19q13.33   1081
hsa-miR-518d 19q13.33   3787 KLK2
hsa-miR-516b-1 19q13.33   1882 KLK2, KLK3, KLK10
hsa-miR-518a-2 19q13.33   2399
hsa-miR-517c 19q13.33   1894 KLK2
hsa-miR-520h 19q13.33   1105 KLK10
hsa-miR-521-1 19q13.33   6037
hsa-miR-522 19q13.33   2489 KLK3, KLK10
hsa-miR-519a-1 19q13.33   1100 KLK7
hsa-miR-527 19q13.33   1537 KLK12
hsa-miR-516a-1 19q13.33   2639 KLK9
hsa-miR-1283-2 19q13.33   1402
hsa-miR-516a-2 19q13.33   2815 KLK9
hsa-miR-519a-2 19q13.33   1122 KLK7
4 hsa-miR-371 19q13.33 - KLK2, KLK10
hsa-miR-372 19q13.33   149 KLK5, KLK10
hsa-miR-373 19q13.33   749 KLK2, KLK5, KLK10
 
a
 KLKs were only listed if they were predicted to be targeted by at least three programs. 
that were located at sites of reported chromosomal aberrations 
in PCa. Fifty-nine percent (13/22) miRNAs were reported to 
be correlated with the direction of chromosomal change in 
PCa; e.g., miR-449 and miR-449a are downregulated in PCa 
and located at Ch 5q11.2, which has been reported to have 
chromosomal losses in PCa (Table  3 ). These data suggest 
that chromosomal changes may, in part, contribute to miRNA 
dysregulation in PCa. 
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 Table 4  A complied list of 16 miRNAs that are dysregulated in PCa, predicted to target KLKs and have been validated to target other genes 
involved in prostate carcinogenesis. 
miRNA Expression in PCa Validated targets References
miR-107 Up / Down GRN (Wang et al. , 2010 )
miR-143 Down MYO6, KRAS, ERK5, ICP4 (Clape et al. , 2009 ; Lee et al. , 2009a ; Szczyrba et al. , 2010 ; Xu 
et al. , 2011 )
miR-145 Down MYO6, ICP4, SWAP70, 
FSCN1, TNFSF10
(Lee et al. , 2009a ; Szczyrba et al. , 2010 ; Zaman et al. , 2010 ; 
Chiyomaru et al. , 2011 ; Fuse et al. , 2011 )
miR-15 Down BCL2, CCND1, WNT3A (Bonci et al. , 2008 )
miR-16 Up BCL2, CCND1, WNT3A (Bonci et al. , 2008 )
miR-200b Up ZEB2 (Kong et al. , 2009 )
miR-205 Down BCL2 (Bhatnagar et al. , 2010 )
miR-21 Up BMPRII, MARCKS, 
PDCD4, PTEN, ANP32A, 
SMARCA4, SPRY1
(Qin et al. , 2009 ; Finlayson and Freeman , 2009 ; Shi et al. , 
2010 ; Yang et al. , 2010 ; Darimipourain et al. , 2011 ; Liu et al. , 
2011b ; Schramedei et al. , 2011 )
miR-24 Up FAF1 (Qin et al. , 2010 )
miR-31 Up E2F6 (Bhatnagar et al. , 2010 )
miR-330-3p Down E2F1 (Lee et al. , 2009b )
miR-331-3p Down ERBB2, PSA (Epis et al. , 2009 )
miR-34a Down CD44, SIRT1, BCL2 (Fujita et al. , 2008 ; Kojima et al. , 2010 ; Liu et al. , 2011a )
miR-34c Down E2F3, BCL2 (Hagman et al. , 2010 )
miR-449a Down HDAC-1, CCND1 (Noonan et al. , 2009 ; Noonan et al. , 2010 )
miR-7 Down EGFR (Giles et al. , 2011 )
serine/theronine-protein kinase (PI3K/Akt) signaling pathway 
(Sarkar et al. , 2010 ). A major component of this pathway 
is the tumor suppressor phosphatase and tensin homolog 
(PTEN), which normally functions to block the activity of 
PI3K. Another pathway that is frequently dysregulated in PCa 
includes the androgen receptor (AR) pathway. 
 miR-331-3p, which is decreased in PCa and is predicted to 
target KLK2 and KLK4, has been shown to target two spe-
cifi c sites within the human ERBB2 mRNA 3 ′ untranslated 
region. Transfection of multiple PCa cell lines with miR-331 
showed a reduction of ERBB2 mRNA and protein expression 
and a block of the downstream PI3K/Akt signaling pathway. 
miR-331-3p was also shown to block androgen signaling 
and reduce the activity of the PSA promoter, subsequently 
decreasing PSA expression (Epis et al. , 2009 ). 
 miR-21, which is described as an oncomir, has been shown 
to have increased expression in almost all cancers includ-
ing PCa. Validated targets for miR-21 in PCa include bone 
morphogenetic protein receptor, type II (BMPRII), myris-
toylated alanine-rich protein kinase C substrate (MARCKS), 
programmed cell death 4 (PDCD4), PTEN, acidic (leu-
cine-rich) nuclear phosphoprotein 32 family, member A 
(ANP32A), SWItch/Sucrose NonFermentable (SWI/SNF) 
related, matrix-associated, actin-dependent regulator of chro-
matin, subfamily a, member 4 (SMARCA4), and sprouty 1 
(SPRY1; Table 4). Yang et al. showed that when miR-21 was 
ectopically expressed in PCa cells, phosphorylation of Akt 
was induced by interferon but not induced in cells that do 
not express miR-21 (Yang et al. , 2010 ). In addition, it has 
been shown that miR-21 can target the tumor suppressor 
PTEN (Liu et al. , 2011a ). Ribas et al. showed that AR can 
directly interact with miR-21 regulatory regions, indicating 
 Table 3  miRNAs that are dysregulated in PCa are located at sites of 
frequently reported chromosomal aberrations. 
miRNA miRNA 
dysregulation
Chromosomal 
location
Reported 
chromosomal 
changes
miR-1 Up 20q13.33 Gain
miR-106b Up   7q22.1 Gain
miR-24 Up   9q22.32 Gain
miR-30d Down   8q24.22 Gain
miR-32 Up   9q31.3 Gain
miR-96 Up   7q32.2 Gain
miR-107 Down 10q23.31 Loss
miR1296 Down 10q21.3 Loss
miR-140 Down 16q22.1 Loss
miR-15 Down 13q14.2 Loss
miR-324-3p Down 17p13.1 Loss
miR-449 Down   5q11.2 Loss
miR-449a Down   5q11.2 Loss
 Involvement of dysregulated miRNAs in the patho-
genesis of PCa  To examine the role of miRNAs that are 
dysregulated in PCa and can target KLKs in PCa pathogenesis, 
we did target prediction analysis for these 29 miRNAs and 
examined their potential interaction with pathways that are 
frequently dysregulated in PCa (Table  4 ). We found that 
16 of these miRNAs were validated to target components 
of pathways frequently dysregulated in PCa. One of these 
pathways that are hyperactivated in approximately 30 % –
50 % of PCas is the phophatidylinositol 3-kinase/RAC-alpha 
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direct transcriptional induction (Ribas et al. , 2009 ). They 
also found that overexpression of miR-21 enhanced tumor 
xenograft growth and was suffi cient to support androgen-
independent proliferation following surgical castration. Taken 
together, our data shows that KLKs can be involved in a net-
work of interactions that are involved in PCa pathogenesis. 
 Discussion 
 Kallikreins have been shown to be involved in a number of 
different cancers, yet the mechanisms controlling their dys-
regulation are still uncertain for many cases. It is hypothe-
sized that, in part, this regulation may be posttranscriptional 
through miRNAs (Chow et al. , 2008 ; Yousef , 2008 ). We 
showed evidence indicating that miRNAs can contribute to 
KLK dysregulation in PCa through two independent lines 
of evidence. First, we observed a pattern of inverse correla-
tion between dysregulated miRNAs and their target KLKs, 
miR-143 and its target KLK2, and miR-331-3p and its target 
KLK4 in PCa tissue (Figure 2), indicating that the miRNAs 
may control KLK expression in PCa. In addition, we showed 
that transfection of miR-143 into a PCa cell line model 
decreased KLK2 expression and cellular growth. This, how-
ever, must be interpreted with caution. It must be noted that 
miR-143 can have other targets that may contribute to this 
biological effect. Overexpression of miR-143 has been shown 
to suppress PCa proliferation and migration and increase 
sensitivity to docetaxel by targeting the mitogen-activated 
protein kinase signaling (EGFR/RAS/MAPK) pathway 
(Xu et al. , 2011 ). Other targets that have been validated 
for miR-143 in PCa include extracellular signal-regulated 
kinase-5 (ERK5) (Clape et al. , 2009 ) and genes involved in 
epithelial to mesenchymal transition (Peng et al. , 2011 ). 
 The fact that miRNAs have multiple targets and can target 
more than one gene has important implications. On one hand, 
the targeting of a number of genes in the same pathway has 
potential therapeutic implications. In this case, the introduc-
tion of a miRNA can target or  ‘ hit ’ the pathway at multiple 
points, which increases the chances of successful pathway 
suppression (Metias et al. , 2009 ; White and Yousef , 2011 ). On 
the other hand, because miRNAs can have a number of targets 
in different pathways, it is experimentally challenging to con-
trol for off-target effects. This needs solid experimental design, 
combination of bioinformatics and experimental approaches, 
and the use multiple independent validation techniques. 
 We preformed bioinformatics analyses to explore the 
mechanism of miRNA dysregulation in PCa. The coordinated 
dysregulation of miRNA clusters, miRNAs that are located in 
close proximity, implies a coordinated regulation and func-
tion. Our analysis showed that the KLK locus, Ch 19q13, 
harbors a large number of miRNAs. This miRNA cluster, 
which has been termed C19MC, represents the largest cluster 
in the human genome (Bentwich et al. , 2005 ). Interestingly, 
an amplicon of this region was found to be associated with 
an aggressive subgroup of primitive neuroectodermal tumors 
with distinct gene-expression profi les, characteristic his-
tology, and dismal survival (Li et al. , 2009a ). Coordinated 
expression of miRNAs within clusters suggests a coordinated 
control mechanism and functions. Similarly, it has been sug-
gested that KLKs share a similar control mechanism and 
function. It would be interesting to explore if a relationship 
exists between the two. 
 Other groups have examined the miRNA-KLK interaction 
in PCa by examining the relationship between miRNAs and 
PSA (KLK3) in PCa. Transfection of miR-99a, miR-99b, or 
miR-100 inhibited the growth of PCa cells and decreased the 
expression of PSA (KLK3) in PCa cell lines (Sun et al. , 2011 ). 
PSA levels increased after inhibition of the miR-99 family, sug-
gesting that miRNAs can contribute to PSA regulation in PCa. 
 miRNAs represent attractive useful clinical markers for 
PCa, and evidence for this use is emerging quickly. Hoa et al. 
reported an increase in the positive predictive value in PCa 
patients from 40 % to 87.5 % by integrating PSA blood lev-
els with miR-21 and miR-141 profi les (Hao et al. , 2011 ). It 
has also been reported that a panel of markers including 10 
protein-coding genes and two miRNAs, miR-519d and miR-
647, was identifi ed to accurately separate patients with and 
without biochemical recurrence ( p < 0.001), as well as for the 
subset of 42 Gleason score of[FCP1] seven patients ( p < 0.001) 
(Long et al. , 2011 ). More recently, circulating miR-141 lev-
els in the plasma of PCa patients predicted clinical outcomes 
with an odds ratio of at least 8.3 (Gonzales et al. , 2011 ). In 
the same study, miR-141 also had the highest correlation 
with temporal changes of PSA and demonstrated high cor-
relation with changes of the other biomarkers. Circulating 
tumor markers represent attractive clinical markers as their 
non-invasive nature if superior to prostatectomy. 
 Through our study and others, it is now evident that the 
miRNA-KLK interaction is involved in PCa pathogenesis 
and has potential clinical utilities. However, this relationship 
is more complex than previously thought. One miRNA can 
target more than one KLK, and one KLK can be targeted by 
more than one miRNA leading to a complex network of inter-
actions (Figure 1). In addition, these interactions may be direct 
or indirect, which adds to the complexity. Although miRNAs 
act posttranscriptionally, recent evidence supports that they 
also usually interfere with the stability of their target mRNAs 
(Cheng and Li , 2008 ; Gennarino et al. , 2009 ; Guimbellot 
et al. , 2009 ) Moreover, KLKs may also contribute to miRNA 
regulation through transcriptional regulation of miRNA pro-
moters as suggested by KLK nuclear localization (Korkmaz 
et al. , 2001 ; Klokk et al. , 2007 ). 
 In conclusion, we provide bioinformatics and experimental 
evidence suggesting that miRNAs are involved in the regula-
tion of KLKs and that both can actively contribute to PCa 
formation and progression. 
 Materials and methods 
 Sample collection 
 The study was approved by the Research Ethics Boards of 
St. Michael ’ s Hospital, Toronto, Canada, and Charit é -University 
Hospital, Berlin, Germany. Fresh prostate tissues from 12 pairs of tumor 
and normal tissues from the same patients were sampled directly after 
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surgical removal of the gland for treatment of PCa at Charit é -University 
Hospital, Berlin, Germany. One full frontal section, which was grossly 
tumor suspicious, was deep frozen in liquid nitrogen. A diagnostic he-
matoxylin and eosin section was prepared to verify tumor content and 
margin status and to identify areas of normal and tumor tissue. These 
regions of interest were punch biopsied, and another frozen section was 
made to ascertain tumor content and to assign a Gleason score. Only 
cases with  > 90 % tumor tissue were considered for further analysis. 
 miRNA dysregulation in PCa 
 In order to create a comprehensive list of miRNAs dysregulated 
in PCa, we combined data from our recently published miRNA 
microarray comparing PCa with normal matched prostate tissue from 
the same patient (Schaefer et al. , 2010a ) and did a literature search 
for additional reported miRNAs dysregulated in PCa when compared 
to normal prostate tissue (Sylvestre et al. , 2007 ; Ambs et al. , 2008 ; 
Shi et al. , 2011 ; Sun et al. , 2011 ). 
 Total RNA extraction and reverse transcription 
 Frozen matched malignant and non-malignant samples were collected 
in RNAlater Stabilization reagent (Qiagen GmbH, Hilden, Germany). 
RNA was extracted with the RNA miR Isolation Kit (Qiagen). Total 
RNA yields and A260/280 ratio were monitored with a NanoDrop 
2000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, 
USA), and RNA integrity numbers were measured with the 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only 
RNA extracts with RNA integrity number values  > 6 were included in 
further analysis. Samples were stored at -80 ° C until further use. 
 One microgram of total RNA was reverse transcribed using 
the Transcriptor First Strand cDNA Synthesis Kit (Roche Applied 
Science, Indianapolis, IN, USA) following the manufacturer ’ s 
recommendation. 
 qRT-PCR 
 qRT-PCR was performed using the Step One ™ Plus Real-Time PCR 
System (Applied Biosystems, Foster City, CA, USA). Primer/probe 
sets were purchased as premade TaqMan Assays on Demand for  KLK2 
(Hs00428383_m1),  KLK3 (Hs02576345_m1),  KLK4 (Hs00191772_
m1), and  KLK10 (Hs00173611_m1). Thermal cycling conditions were 
according to the manufacture ’ s fast protocol, and all reactions were 
performed in triplicate. Relative expression was determined using the 
 Δ Δ C T method, and expression values were normalized to hypoxan-
thine phosphoribosyltransferase 1 (HPRT1) (Hs01003267_m1). 
 miRNA target prediction and validation analysis 
 miRNA target prediction analyses were performed using TargetScan 
5.1 (Lewis et al. , 2005 ) and miRecords (Xiao et al. , 2009 ). 
Experimental target validation of miRNA-KLK interactions were as-
sayed by transfecting the PCa cell line DU-145 with hsa-miR-331-3p 
and hsa-miR-143 (Ambion, Foster City, CA, USA) and comparing 
the expression levels of target KLKs before and after transfection. 
Cells were transfected using the si-PORT ™  NeoFX ™ transfection 
system (Ambion) according to the manufacturer ’ s protocol. miRNA 
precursors, hsa-miR-331-3p, hsa-miR-143, and a random sequence 
control (Applied Biosystems) were added at a fi nal concentration 
of 5 nm. Transfection agent/RNAmolecule complex formation was 
carried out in Opti-MEM Reduced-Serum Media (1X; Invitrogen, 
Burlington, ON, Canada). The DU-145 cell line was maintained in 
RPMI 1640 supplemented with 10 % fetal bovine serum (Invitrogen, 
Burlington, Canada) in 5 % CO 2 and 37 ° C. 
 Cell proliferation assay 
 Cellular proliferation was measured by cell counting. DU-145 cells 
were plated at 8.0 × 10 4 cells per well in a 12-well plate and were 
either untransfected or transfected with miR-143, miR-331-3p, or a 
random sequence control miRNA. Cells were incubated for 1–4 days 
after which they were trypsinized and counted. Cells were counted in 
triplicate and repeated thrice. 
 In silico analysis 
 Chromosomal aberrations in PCa were extracted from the 
Progenetix database ( www.progenetix.net ). Average genetic 
changes from 687 cases of PCa were used for comparative ge-
nomic hybridization analysis. We also did a literature search for 
cytogenetic aberrations in PCa (Nupponen and Visakorpi , 2000 ; 
Brothman , 2002 ; Gu and Brothman , 2011 ). Results were compiled 
and were then compared to the chromosomal locations of dysregu-
lated miRNAs in PCa. 
 miRNA clusters were defi ned as miRNAs, which lie within 10 000 
nucleotides (inter-miRNA distance) from one another. The distance 
between miRNA and their chromosomal locations were determined 
using the latest release (Release 17) of miRBase and the UCSC ’ s 
Genome Browser and Track feature. 
 Sequence homology and multiple alignment tools were performed 
using miROrtho (Faculty of Medicine, University of Geneva), which 
contains predictions of miRNA genes covering several animal 
genomes. Built into miROrtho is a T-COFFEE (version 6.92) output 
for the multiple sequence alignment. High conservation was defi ned 
as sequences having an alignment reliability core index  > 80. 
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